Teriparatide

FDA · Forteo

26 Nov 2002 · Osteoporosis, Postmenopausal Women With Osteoporosis, fractures

EMA · Forsteo

10 Jun 2003 · Osteoporosis, Osteoporosis, Postmenopausal, Hip Fractures, fractures

EMA · Terrosa

4 Jan 2017 · Osteoporosis, Hip Fractures, fractures

EMA · Movymia

11 Jan 2017 · Osteoporosis, Hip Fractures, fractures

FDA · Bonsity

4 Oct 2019 · Osteoporosis, Postmenopausal Women With Osteoporosis, fractures

EMA · Livogiva

27 Aug 2020 · Osteoporosis, Hip Fractures, fractures

Heart disease

Phase 4 · Recruiting · 1 trial

Bone fracture

Phase 4 · Status unknown · 2 trials

Rheumatoid arthritis

Phase 4 · Results posted · 1 trial

Spinal cord injury

Phase 4 · Results posted · 3 trials

Femoral neck fracture

Phase 3 · Results posted · 2 trials

Hypocalcemia

Phase 3 · Completed · 2 trials

Metabolic bone disease

Phase 4 · Results posted · 8 trials

Chronic Kidney Disease-Mineral and Bone Disorder

Phase 4 · Recruiting · 2 trials

Hypoparathyroidism

Phase 3 · Completed · 5 trials

Stress Fractures

Phase 3 · Completed · 2 trials

Secondary hyperparathyroidism

Phase 3 · Completed · 1 trial

Central nervous system disease

Phase 2 · Results posted · 1 trial

NCT00446589 · Terminated · Osteoporosis

due to financial problems

NCT00393380 · Terminated · Aplastic anemia

Study stopped because of toxicity concerns.

NCT01679080 · Terminated · Osteogenesis imperfecta

Eli Lilly has withdrawn support to the study of teriparatide and placebo pens. The study was not able to continue as a randomized study without the supply of placebo pens.